---
title: "Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Friday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274363151.md"
description: "Corbus Pharmaceuticals Holdings Inc. (CRBP) shares fell 4.17% to $8.27 on Friday, marking the third consecutive day of losses. The stock is currently 59.78% below its 52-week high of $20.56. In comparison, competitors Vanda Pharmaceuticals (VNDA), Fortress Biotech (FBIO), and Viking Therapeutics (VKTX) also experienced declines. The NASDAQ Composite Index dropped 0.94%, while the Dow Jones Industrial Average fell 0.36%. Trading volume was significantly below the 50-day average."
datetime: "2026-01-30T22:22:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274363151.md)
  - [en](https://longbridge.com/en/news/274363151.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274363151.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274363151.md) | [繁體中文](https://longbridge.com/zh-HK/news/274363151.md)


# Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Friday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) shed 4.17% to $8.27 Friday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index falling 0.94% to 23,461.82 and Dow Jones Industrial Average falling 0.36% to 48,892.47. This was the stock's third consecutive day of losses. Corbus Pharmaceuticals Holdings Inc. closed 59.78% short of its 52-week high of $20.56, which the company reached on October 20th. The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Vanda Pharmaceuticals Inc. (VNDA) fell 3.08% to $7.54, Fortress Biotech Inc. (FBIO) fell 7.74% to $3.10, and Viking Therapeutics Inc. (VKTX) fell 3.97% to $29.04. Trading volume (108,853) remained 215,831 below its 50-day average volume of 324,684. Data source: Dow Jones Market Data, FactSet. Data compiled January 30, 2026. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 01-30-26 1722ET

### Related Stocks

- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [Corbus Pharmaceuticals Holdings, Inc. (CRBP.US)](https://longbridge.com/en/quote/CRBP.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Viking Therapeutics, Inc. (VKTX.US)](https://longbridge.com/en/quote/VKTX.US.md)
- [Fortress Biotech, Inc. (FBIO.US)](https://longbridge.com/en/quote/FBIO.US.md)
- [Vanda Pharmaceuticals Inc. (VNDA.US)](https://longbridge.com/en/quote/VNDA.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Viking Therapeutics to Participate at Upcoming Investor Conferences | VKTX Stock News](https://longbridge.com/en/news/277985746.md)
- [Xeris Biopharma Q4 product revenue beats analyst expectations, driven by higher patient demand](https://longbridge.com/en/news/277460502.md)
- [BUZZ-MAIA Biotechnology plunges after $30 million share sale](https://longbridge.com/en/news/277605454.md)
- [TD Asset Management Inc Increases Position in Nuvalent, Inc. $NUVL](https://longbridge.com/en/news/277627358.md)
- [FDA approves Ascendis Pharma’s weekly Yuviwel for paediatric dwarfism](https://longbridge.com/en/news/277455732.md)